ArticleMolecular cancer research : MCR2009
Caveolin-1 promotes autoregulatory, Akt-mediated induction of cancer-promoting growth factors in prostate cancer cells.
Article in Molecular cancer research : MCR, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 43 citations in OpenAlex.
- Antitumor Activity of Taxol Engross Taxol-Caveolin-1 Interaction via Lipid Raft Structure-"Caveolae".Applied biochemistry and biotechnology · 2023Article
- The role of caveolin-1 in the biofate and efficacy of anti-tumor drugs and their nano-drug delivery systems.Acta pharmaceutica Sinica. B · 2021Review
- Autophagic Inhibition of Caveolin-1 by CompoundFrontiers in pharmacology · 2021Article
- Utility of cytokeratin 7, S100A1 and caveolin-1 as immunohistochemical biomarkers to differentiate chromophobe renal cell carcinoma from renal oncocytoma.Translational andrology and urology · 2019Article
- Expression and clinical significance of Caveolin-1 in prostate Cancer after transurethral surgery.BMC urology · 2018Article
- Caveolin‑1 enhances RANKL‑induced gastric cancer cell migration.Oncology reports · 2018Article
- ITGB1-dependent upregulation of Caveolin-1 switches TGFβ signalling from tumour-suppressive to oncogenic in prostate cancer.Scientific reports · 2018Article
- The level of caveolin-1 expression determines response to TGF-β as a tumour suppressor in hepatocellular carcinoma cells.Cell death & disease · 2017Article
- Versatile Functions of Caveolin-1 in Aging-related Diseases.Chonnam medical journal · 2017Review
- Caveolin-1 regulates hormone resistance through lipid synthesis, creating novel therapeutic opportunities for castration-resistant prostate cancer.Oncotarget · 2016Article
- Estradiol, TGF-β1 and hypoxia promote breast cancer stemness and EMT-mediated breast cancer migration.Oncology letters · 2016Article
- Pigment epithelium-derived factor inhibits caveolin-induced interleukin-8 gene expression and proliferation of human prostate cancer cells.Oncology letters · 2015Article
- Caveolae and signalling in cancer.Nature reviews. Cancer · 2015Review
- Non-caveolar caveolin-1 expression in prostate cancer cells promotes lymphangiogenesis.Oncoscience · 2015Article
- Prognostic value of caveolin-1 in genitourinary cancer: a meta-analysis.International journal of clinical and experimental medicine · 2015Article
- Article
- Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches.Oncogene · 2013Review
- Caveolin-1 in renal cell carcinoma promotes tumour cell invasion, and in co-operation with pERK predicts metastases in patients with clinically confined disease.Journal of translational medicine · 2013Article
- Caveola-forming proteins caveolin-1 and PTRF in prostate cancer.Nature reviews. Urology · 2013Review
- Serum caveolin-1, a biomarker of drug response and therapeutic target in prostate cancer models.Cancer biology & therapy · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
Caveolin-1 (cav-1) and the cancer-promoting growth factors vascular endothelial growth factor (VEGF), transforming growth factor beta1 (TGF-beta1), and fibroblast growth factor 2 (FGF2) are often found to be upregulated in advanced prostate cancer and other malignancies. However, the relationship between cav-1 overexpression and growth factor upregulation remains unclear. This report presents, to our knowledge, the first evidence that in prostate cancer cells, a positive autoregulatory feedback loop is established in which VEGF, TGF-beta1, and FGF2 upregulate cav-1, and cav-1 expression, in turn, leads to increased levels of VEGF, TGF-beta1, and FGF2 mRNA and protein, resulting in enhanced invasive activities of prostate cancer cells, i.e., migration and motility. Our results further show that cav-1-enhanced mRNA stability is a major mechanism underlying the upregulation of these cancer-promoting growth factors, and that PI3-K-Akt signaling is required for forming this positive autoregulatory feedback loop.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.